As consumers taking medications like Ozempic cut back on eating out, about 70% are spending more on cooking at home, ...

Coca-Cola (NYSE:KO) is not seeing the huge effect from GLP-1 usage that some investors feared when the drugs became more ...

Four clinical organizations jointly release an advisory with evidence-based nutrition and lifestyle interventions to enhance ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

IFF is in the early stages of exploring GLP-1 consumer segmentation to help brands move beyond a one-size-fits-all approach toward one grounded in empathy, specificity and long-term relevance. The ...

Although coverage restrictions remain in place, the trendiness of weight loss drugs may be creating a growing cost concern ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. Eli Lilly (NYSE: LLY) has been a ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...